Yoshitaka Honma

3.5k total citations · 1 hit paper
170 papers, 2.3k citations indexed

About

Yoshitaka Honma is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Yoshitaka Honma has authored 170 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Oncology, 97 papers in Pulmonary and Respiratory Medicine and 74 papers in Surgery. Recurrent topics in Yoshitaka Honma's work include Gastric Cancer Management and Outcomes (72 papers), Esophageal Cancer Research and Treatment (45 papers) and Colorectal Cancer Treatments and Studies (35 papers). Yoshitaka Honma is often cited by papers focused on Gastric Cancer Management and Outcomes (72 papers), Esophageal Cancer Research and Treatment (45 papers) and Colorectal Cancer Treatments and Studies (35 papers). Yoshitaka Honma collaborates with scholars based in Japan, United States and United Kingdom. Yoshitaka Honma's co-authors include Yasuhide Yamada, Ken Kato, Satoru Iwasa, Atsuo Takashima, Hirokazu Shoji, Tetsuya Hamaguchi, Natsuko Okita, Koh Furuta, Narikazu Boku and Yasuhiro Shimada and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Yoshitaka Honma

148 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Circulating Exosomal microRNAs as Biomarkers of Colon Cancer

2014 672 citations Yoshitaka Honma, Yasuhide Yamada et al. profile →

Peers

Countries citing papers authored by Yoshitaka Honma

Since Specialization

Citations

This map shows the geographic impact of Yoshitaka Honma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshitaka Honma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshitaka Honma more than expected).

Fields of papers citing papers by Yoshitaka Honma

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshitaka Honma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshitaka Honma. The network helps show where Yoshitaka Honma may publish in the future.

Co-authorship network of co-authors of Yoshitaka Honma

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshitaka Honma. A scholar is included among the top collaborators of Yoshitaka Honma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshitaka Honma. Yoshitaka Honma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Indications for chemoradiotherapy in older patients with locally advanced head and neck cancer in Japan: a questionnaire survey in the JCOG head and neck cancer study group 2025 ·Frontiers in Oncology ·Kôichi Yasuda, (unknown), Kazuto Matsuura, (unknown), Yoshitaka Honma, Yoshinori Imamura, Kaoru Tanaka, Sadamoto Zenda, Takuma Onoe, Takeshi Kodaira, (unknown), Hidefumi Aoyama, Nobuhiro Hanai, Akihiro Homma	0
2	Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study 2025 ·Journal of Clinical Oncology ·Shailender Bhatia, Suzanne L. Topalian, William H. Sharfman, Tim Meyer, Neil Steven, Christopher D. Lao, Lorena Fariñas-Madrid, Lot A. Devriese, Kathleen N. Moore, Robert L. Ferris, Yoshitaka Honma, Ileana Elias, Anjaiah Srirangam, Charlie Garnett‐Benson, Michelle Lee, Paul Nghiem	7
3	EGR1–BDNF–Linking Crosstalk Between Cancer Cells and Nerves for Perineural Invasion in Salivary Duct Carcinoma: Comparison of Salivary Duct Carcinoma De Novo and Ex Pleomorphic Adenoma 2025 ·Laboratory Investigation ·(unknown), Eijitsu Ryo, Seiichi Yoshimoto, Go Omura, Chihiro Fushimi, Toshihiko Sakai, Yoshifumi Matsumoto, (unknown), (unknown), Yo Suzuki, (unknown), Yoshitaka Honma, (unknown), Fumihiko Matsumoto, Taisuke Mori	0
4	Retrospective Analysis of Definitive Chemoradiotherapy With FOLFOX in Patients With Esophageal Cancer Intolerant to Cisplatin 2024 ·In Vivo ·(unknown), Shun Yamamoto, Yoshitaka Honma, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Satoru Iwasa, Atsuo Takashima, Akihito Nagahara, Ken Kato	2
5	An autopsy case of pulmonary tumor thrombotic microangiopathy that developed during chemotherapy for salivary duct carcinoma of the parotid gland 2024 ·Auris Nasus Larynx ·(unknown), (unknown), (unknown), (unknown), (unknown), Yuichiro Tada, (unknown), (unknown), Yasushi Yatabe, Masahiko Kusumoto, Kenichi Nakamura, Yoshitaka Honma	0
6	Early combination with mycophenolate mofetil for immune-related hepatitis in patients with solid tumors treated with immune checkpoint inhibitors. 2024 ·Journal of Clinical Oncology ·(unknown), (unknown), (unknown), (unknown), (unknown), Jun Sato, Yuta Maruki, (unknown), Kenjiro Namikawa, Kazuki Sudo, Yoshitaka Honma, Hironobu Hashimoto, Naoya Yamazaki, Takuji Okusaka, Kan Yonemori, Noboru Yamamoto, (unknown), Ken Kato	2
7	Progression patterns and site‐specific responses in advanced gastric cancer patients treated with nivolumab 2023 ·Cancer Medicine ·(unknown), Satoru Iwasa, Kengo Nagashima, (unknown), Shun Yamamoto, Hidekazu Hirano, Natsuko Okita, Hirokazu Shoji, Yoshitaka Honma, Atsuo Takashima, Ken Kato, Toshikazu Ushijima, Narikazu Boku	2
8	Comparison of Survival Outcomes Between Larynx-Preserving Open Partial Pharyngectomy and Radiotherapy or Chemoradiotherapy in Patients with Hypopharyngeal Squamous Cell Carcinoma: A Single-Center Retrospective Analysis with Inverse Probability of Treatment Weighting Adjustments 2023 ·Annals of Surgical Oncology ·(unknown), Go Omura, Naoya Murakami, Yoshitaka Honma, (unknown), (unknown), (unknown), (unknown), Yoshifumi Matsumoto, Toshihiko Sakai, Kenya Kobayashi, Hiroshi Igaki, Seiichi Yoshimoto	1
9	Clinical and pathological features of second primary neoplasms arising in head and neck reconstructive skin flaps 2023 ·Scientific Reports ·(unknown), Kenya Kobayashi, Yoshitaka Honma, Eijitsu Ryo, (unknown), (unknown), (unknown), (unknown), (unknown), Yoshifumi Matsumoto, Toshihiko Sakai, Go Omura, Yasushi Yatabe, Seiichi Yoshimoto, Taisuke Mori	3
10	1203P Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213 2023 ·Annals of Oncology ·(unknown), Chigusa Morizane, Nozomu Machida, Yoshitaka Honma, Takuji Okusaka, Narikazu Boku, Ken Kato, Gakuto Ogawa, Y. Sano, Hiroshi Imaoka, Satoshi Kobayashi, Takeshi Terashima, Masafumi Ikeda, Naohiro Okano, Kensei Yamaguchi, Tosiya Sato, Nobumasa Mizuno, Yuko Kitagawa, Masanori Terashima, Makoto Ueno	1
11	Transnasal photoimmunotherapy with cetuximab sarotalocan sodium: Outcomes on the local recurrence of nasopharyngeal squamous cell carcinoma 2022 ·Auris Nasus Larynx ·Go Omura, Yoshitaka Honma, Yoshifumi Matsumoto, Takeshi Shinozaki, (unknown), (unknown), Toshihiko Sakai, (unknown), (unknown), (unknown), Ken Kato, Seiichi Yoshimoto	20
12	A mimic of lung adenocarcinoma: a case report of histological conversion of metastatic thyroid papillary carcinoma 2021 ·Histopathology ·(unknown), Jumpei Kashima, Taiki Hashimoto, Hitoshi Ichikawa, Yoshitaka Honma, Yasushi Goto, Shun‐ichi Watanabe, Yasushi Yatabe	1
13	Full-coverage TP53 deep sequencing of recurrent head and neck squamous cell carcinoma facilitates prognostic assessment after recurrence 2020 ·Oral Oncology ·Kenya Kobayashi, Seiichi Yoshimoto, Mizuo Ando, Fumihiko Matsumoto, Naoya Murakami, Go Omura, Yoshitaka Honma, Yoshifumi Matsumoto, (unknown), (unknown), (unknown), (unknown), (unknown), Yasushi Yatabe, Taisuke Mori	7
14	Study protocol for a multi-institutional randomized phase III study comparing combined everolimus plus lanreotide therapy and everolimus monotherapy in patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors; Japan Clinical Oncology Group Study JCOG1901 (STARTER-NET study) 2020 ·Pancreatology ·Ryo Shimoyama, Susumu Hijioka, Nobumasa Mizuno, Gakuto Ogawa, Tomoko Kataoka, Hiroshi Katayama, Nozomu Machida, Yoshitaka Honma, Narikazu Boku, Tetsuya Hamaguchi, Haruhiko Fukuda, Masanori Terashima, Yukihide Kanemitsu, Junji Furuse	7
15	Efficacy of trastuzumab emtansine in Japanese patients with previously treated HER2‐positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: A subgroup analysis of the GATSBY study 2019 ·Asia-Pacific Journal of Clinical Oncology ·Kohei Shitara, Yoshitaka Honma, Yasushi Omuro, Kensei Yamaguchi, Keisho Chìn, Kei Muro, (unknown), (unknown), Shuichi Hironaka, Tomohiro Nishina	13
16	Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer 2019 ·International Journal of Clinical Oncology ·Ryo Otsuka, Satoru Iwasa, Takako Yanai, Hidekazu Hirano, Hirokazu Shoji, Yoshitaka Honma, Natsuko Okita, Atsuo Takashima, Ken Kato, Hironobu Hashimoto, (unknown), Yoshinori Makino, Narikazu Boku, Masakazu Yamaguchi	5
17	Prognostic value of the expression of epithelial cell adhesion molecules in head and neck squamous cell carcinoma treated by definitive radiotherapy 2019 ·Journal of Radiation Research ·Naoya Murakami, Taisuke Mori, Satoshi Nakamura, Seiichi Yoshimoto, Yoshitaka Honma, (unknown), Kenya Kobayashi, Tairo Kashihara, Kana Takahashi, Koji Inaba, Kae Okuma, Hiroshi Igaki, Yuko Nakayama, Jun Itami	8
18	Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients 2016 ·Cancer Science ·Satoru Iwasa, Yasuhide Yamada, Yuji Heike, Hirokazu Shoji, Yoshitaka Honma, Nobukazu Komatsu, Satoko Matsueda, Akira Yamada, (unknown), Rin Yamaguchi, Natsuki Tanaka, Akihiko Kawahara, Masayoshi Kage, Shigeki Shichijo, Tetsuro Sasada, Kyogo Itoh	10
19	Pretreatment Immune Status Correlates with Progression-Free Survival in Chemotherapy-Treated Metastatic Colorectal Cancer Patients 2016 ·Cancer Immunology Research ·Kohei Tada, Shigehisa Kitano, Hirokazu Shoji, Takashi Nishimura, Yasuhiro Shimada, Kengo Nagashima, Kazunori Aoki, Nobuyoshi Hiraoka, Yoshitaka Honma, Satoru Iwasa, Natsuko Okita, Atsuo Takashima, Ken Kato, Yasuhide Yamada, Naoyuki Katayama, Narikazu Boku, Yuji Heike, Tetsuya Hamaguchi	54
20	Irinotecan plus cisplatin in patients with extensive-disease poorly differentiated neuroendocrine carcinoma of the esophagus. 2014 ·PubMed ·Hitomi Sumiyoshi Okuma, Satoru Iwasa, Hirokazu Shoji, Atsuo Takashima, Natsuko Okita, Yoshitaka Honma, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada, Yasuhiro Shimada	24

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact